Market Place
Sourcing Support
Ono Acquires Deciphera Pharmaceuticals
12 Jun 2024 //
CONTRACT PHARMA
Deciphera`s MOTION Data, Vimseltinib In TGCT In The Lancet, At ASCO
03 Jun 2024 //
BUSINESSWIRE
Deciphera had another bidder before Ono deal
13 May 2024 //
ENDPTS
ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals
30 Apr 2024 //
PR NEWSWIRE
Japan`s Ono to buy US drugmaker Deciphera for $2.4 bln
30 Apr 2024 //
REUTERS
Why Is Deciphera Pharmaceuticals Stock Up 72% Today?
29 Apr 2024 //
INVESTOT PLACE
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
29 Apr 2024 //
BUSINESSWIRE
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
27 Feb 2024 //
BUSINESSWIRE
Deciphera Announces Fourth Quarter and Full Year 2023 Financial Results
06 Feb 2024 //
BUSINESSWIRE
Deciphera Pharmaceuticals to Present at the 6th Annual Biotechnology Conference
01 Feb 2024 //
BUSINESSWIRE
Deciphera Pharma to Announce Fourth Quarter and Full Year 2023 Financial Results
01 Feb 2024 //
BUSINESSWIRE
Deciphera Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Study
18 Jan 2024 //
BUSINESSWIRE
GENESIS Pharma Announces an Exclusive Distribution Agreement with Deciphera
12 Jan 2024 //
BUSINESSWIRE
Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones
08 Jan 2024 //
BUSINESSWIRE
Deciphera Announces Results from ctDNA Analysis from INTRIGUE Phase 3
05 Jan 2024 //
BUSINESSWIRE
Deciphera to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
BUSINESSWIRE
Deciphera to Present at the JMP Securities Hematology and Oncology Summit
29 Nov 2023 //
BUSINESSWIRE
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
07 Nov 2023 //
BUSINESSWIRE
Deciphera`s tumor-tackling oral med achieves 40% response rate
31 Oct 2023 //
FIERCE BIOTECH
Deciphera Announces Positive Results from Phase 3 Study of Vimseltinib
30 Oct 2023 //
BUSINESSWIRE
Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results
30 Oct 2023 //
PRESS RELEASE
Deciphera Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15 Sep 2023 //
BUSINESSWIRE
Deciphera Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 Aug 2023 //
BUSINESSWIRE
Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results
09 Aug 2023 //
BUSINESSWIRE
Deciphera Announces Appointment of Dashyant Dhanak as Executive VP
03 Aug 2023 //
BUSINESSWIRE
Deciphera Pharmaceuticals to Announce Second Quarter 2023 Financial Results
02 Aug 2023 //
BUSINESSWIRE
Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK
25 May 2023 //
BUSINESSWIRE
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
23 May 2023 //
BUSINESSWIRE
Deciphera Pharmato Present at the JMP Securities Life Sciences Conference
08 May 2023 //
BUSINESSWIRE
Deciphera to Announce First Quarter 2023 Financial Results and Host Conference
26 Apr 2023 //
BUSINESSWIRE
Deciphera Pharmato Present at the Stifel Virtual Targeted Oncology Days
19 Apr 2023 //
BUSINESSWIRE
Deciphera Announces Presentations Highlighting Discovery Research Programs
14 Mar 2023 //
BUSINESSWIRE
Deciphera Pharmaceuticals Announces QINLOCK Included in NCCN Guidelines
14 Mar 2023 //
BUSINESSWIRE
Deciphera Announces Completion of Enrollment for PIII Study of Vimseltinib
01 Mar 2023 //
BUSINESSWIRE
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
27 Feb 2023 //
BUSINESSWIRE
Deciphera Announces Fourth Quarter and Full Year 2022 Financial Results
07 Feb 2023 //
BUSINESSWIRE
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
02 Feb 2023 //
BUSINESSWIRE
Deciphera to Announce Fourth Quarter and Full Year 2022 Financial Results
31 Jan 2023 //
BUSINESSWIRE
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock
24 Jan 2023 //
BUSINESSWIRE
Deciphera Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Study
24 Jan 2023 //
BUSINESSWIRE
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
19 Jan 2023 //
BUSINESSWIRE
After hashing out comeback plans, Deciphera looks to raise $125M from stock sale
19 Jan 2023 //
ENDPTS
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock
18 Jan 2023 //
BUSINESSWIRE
Deciphera revives hopes for Qinlock with subgroup analysis, plots new PhIII
04 Jan 2023 //
ENDPTS
Deciphera Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Study
03 Jan 2023 //
PRESS RELEASE
Deciphera Pharmaceuticals to Present at the 41st Annual J.P. Morgan Conference
03 Jan 2023 //
BUSINESSWIRE
Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones
03 Jan 2023 //
BUSINESSWIRE
Deciphera to Present at the JMP Securities Hematology and Oncology Summit
01 Dec 2022 //
BUSINESSWIRE
Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
08 Nov 2022 //
BUSINESSWIRE
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results
03 Nov 2022 //
BUSINESSWIRE
Deciphera to Announce Third Quarter 2022 Financial Results
27 Oct 2022 //
BUSINESSWIRE
Deciphera Presents Updated Phase 1/2 Data for Vimseltinib in TGCT
11 Sep 2022 //
BUSINESSWIRE
Deciphera Presents Phase 1 Single Agent Dose Escalation Data for DCC-3116
10 Sep 2022 //
BUSINESSWIRE
Deciphera to Host Virtual Investor Event to Discuss DCC-3116 & Vimseltinib Data
01 Sep 2022 //
BUSINESSWIRE
Deciphera (DCPH) Thrives on Qinlock, Overdependence a Concern
30 Aug 2022 //
NASDAQ
Deciphera Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 Aug 2022 //
BUSINESSWIRE
Deciphera Pharma Announces Publication of INTRIGUE Phase 3 Clinical Study
10 Aug 2022 //
BIOSPACE
Deciphera Pharma Announces Publication of Phase 3 Clinical Study Results
10 Aug 2022 //
BUSINESS WIRE
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results
04 Aug 2022 //
BUSINESSWIRE
Deciphera Pharma to Announce Second Quarter 2022 Financial Results
28 Jul 2022 //
BUSINESSWIRE
